Karyopharm Therapeutics Inc. (KPTI)

Market Cap	75.54M
Revenue (ttm)	145.24M
Net Income (ttm)	-76.42M
Shares Out	126.24M
EPS (ttm)	-0.93
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,053,673
Open	0.602
Previous Close	0.610
Day's Range	0.590 - 0.625
52-Week Range	0.530 - 1.700
Beta	0.06
Analysts	Strong Buy
Price Target	5.00 (+735.56%)
Earnings Date	Feb 19, 2025

About KPTI

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myelom...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 6, 2013
• Employees: 325
• Stock Exchange: NASDAQ
• Ticker Symbol: KPTI
• Website: https://www.karyopharm.com

Financial Performance

In 2024, Karyopharm Therapeutics's revenue was $145.24 million, a decrease of -0.55% compared to the previous year's $146.03 million. Losses were -$76.42 million, -46.60% less than in 2023.

Analyst Forecast

According to 4 analysts, the average rating for KPTI stock is "Strong Buy." The 12-month stock price forecast is $5.0, which is an increase of 735.56% from the latest price.

Price Target

$5.0

(735.56% upside)

Analyst Consensus: Strong Buy